Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
This was a sham controlled study for the first three months. Patients had one eye designated as the study eye and were randomized to receive one of two study treatments (CXL or sham) in their study eye. The patients were evaluated at 1, 3, 6, and 12 months. At month 3 or later patients had the option of receiving CXL treatment in both the sham and non-study eye.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Corneal Collagen Cross-linking (CXL) Treatment Group | Active Comparator | riboflavin ophthalmic solution and UVA irradiation |
|
| Control Group | Sham Comparator | riboflavin ophthalmic solution without UVA irradiation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| riboflavin ophthalmic solution | Drug | riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in Maximum Keratometry (Kmax) | The primary efficacy parameter was corneal curvature, as measured by maximum keratometry (Kmax) in the study eyes. Study success was defined as a difference of ≥1 D in the mean change in Kmax from baseline to 12 months between the CXL group and control group. Keratometry was measured manually and by pentacam. | baseline,12 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Hersh, MD | Cornea and Laser Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shiley Eye Center | La Jolla | California | 92093 | United States | ||
| Gordon -Weiss Vision Institute |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22692521 | Derived | Greenstein SA, Fry KL, Hersh PS. Effect of topographic cone location on outcomes of corneal collagen cross-linking for keratoconus and corneal ectasia. J Refract Surg. 2012 Jun;28(6):397-405. doi: 10.3928/1081597X-20120518-02. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Corneal Collagen Cross-linking (CXL) Treatment Group | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes |
| FG001 | Control Group | riboflavin ophthalmic solution without UVA irradiation |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Corneal Collagen Cross-linking (CXL) Treatment Group | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes |
| BG001 | Control Group |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Change From Baseline in Maximum Keratometry (Kmax) | The primary efficacy parameter was corneal curvature, as measured by maximum keratometry (Kmax) in the study eyes. Study success was defined as a difference of ≥1 D in the mean change in Kmax from baseline to 12 months between the CXL group and control group. Keratometry was measured manually and by pentacam. | The ITT (intent to treat) population consisted of all treated subjects, analyzed according to the treatment actually received. For the sham study eyes that received CXL treatment after baseline, the last Kmax measurement recorded prior to receiving CXL treatment was used in the analysis for later time points. | Posted | Mean | Standard Deviation | diopters | baseline,12 months |
|
3 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Corneal Collagen Cross-linking (CXL) Treatment Group | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ulcerative keratitis | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Corneal opacity | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Vineeta Belanger, VP of Clinical Affairs | Avedro, Inc. | 781-768-3459 | vbelanger@avedro.com |
Not provided
| ID | Term |
|---|---|
| D007640 | Keratoconus |
| D003316 | Corneal Diseases |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| UVA Irradiation | Device | UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes |
|
|
| San Diego |
| California |
| 91222 |
| United States |
| Center for Excellence in Eye Care | Miami | Florida | 33176 | United States |
| Price Vision Group | Indianapolis | Indiana | 46260 | United States |
| Durrie Vision | Kansas City | Kansas | 66211 | United States |
| Wilmer Eye Institute at Johns Hopkins University | Baltimore | Maryland | 21287 | United States |
| Minnesota Eye Consultants | Minneapolis | Minnesota | 55404 | United States |
| Cornea & Laser Eye Institute; Hersh Vision Group | Teaneck | New Jersey | 07666 | United States |
| Edward Harkness Eye Institute at Columbia University Medical Center | New York | New York | 10032 | United States |
| Ophthalmic Consultants of Long Island | Rockville Centre | New York | 11570 | United States |
riboflavin ophthalmic solution without UVA irradiation
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG001 | Control Group | riboflavin ophthalmic solution without UVA irradiation |
|
|
| 0 |
| 73 |
| 57 |
| 73 |
| EG001 | Control Group | riboflavin ophthalmic solution without UVA irradiation | 3 | 74 | 25 | 74 |
| Appendicitis | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| infectious cat bite | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Eye pain | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Punctate keratitis | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Corneal striae | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Corneal epithelial defect | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Vision blurred | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Conjunctival hyperaemia | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Photophobia | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Eyelid oedema | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Visual acuity reduced | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Dry Eye | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Eye irritation | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Eye oedema | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Anterior chamber flare | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Corneal disorder | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Lacrimation increased | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Corneal oedema | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Diplopia | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Foreign body sensation in eye | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Glare | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Ocular hyperaemia | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Visual impairment | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Corneal scar | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
Site has the right to publish or communicate study results upon the earlier of: (a) publication of a multi-center publication of the Study results coordinated by Sponsor; or (b) submission of the Study data by Sponsor to the FDA; provided that the Sponsor reviews the proposed communication of results within ninety (90) days in advance of its release. Sponsor can request delay of publication or data release to allow for filing of patent application prior to the publication or release.